Boston Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Boston Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.78M	Buy	+153,446	New	+$8.41M	0.01%	469

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Boston Partners's BMRN Position: Q2 2026 in Review

Boston Partners opened a new position in BioMarin Pharmaceuticals (BMRN) in Q2 2026: 153,446 shares worth $8.78M. The stake represents 0.01% of the portfolio and ranks #469 among its holdings.

416 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Boston Partners held 153,446 shares of BioMarin Pharmaceuticals worth $8.78M as of Q2 2026.
BioMarin Pharmaceuticals was a new Boston Partners position in Q2 2026.
BioMarin Pharmaceuticals made up 0.01% of Boston Partners's portfolio in Q2 2026, its #469 holding.
416 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Boston Partners's 13F filing for Q2 2026, filed 4 Aug 2026.